Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Assets (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Non-Current Assets for 16 consecutive years, with $122.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 27.18% to $122.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $562.8 million through Dec 2025, down 31.99% year-over-year, with the annual reading at $122.7 million for FY2025, 27.18% down from the prior year.
  • Non-Current Assets hit $122.7 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $122.2 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $387.0 million in Q2 2021 to a low of $61.1 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $254.0 million across 5 years, with a median of $254.1 million in 2023.
  • Biggest five-year swings in Non-Current Assets: soared 550.77% in 2021 and later tumbled 42.05% in 2025.
  • Year by year, Non-Current Assets stood at $381.7 million in 2021, then dropped by 16.19% to $319.9 million in 2022, then fell by 25.67% to $237.8 million in 2023, then fell by 29.12% to $168.5 million in 2024, then fell by 27.18% to $122.7 million in 2025.
  • Business Quant data shows Non-Current Assets for IRWD at $122.7 million in Q4 2025, $122.2 million in Q3 2025, and $151.2 million in Q2 2025.